On August 26, 2020, Bayer announced the launch of a prescription drug Beijing factory capacity improvement project to meet the future demand for Bayer's high-quality drugs in the Chinese market. The project has an investment of more than 50 million euros (equivalent to more than 400 million yuan) to increase the production capacity of the Beijing factory on a large scale and accelerate the implementation of innovative digital solutions to ensure a stable supply of Bayer's high-quality prescription drug products and help more Chinese patients Get a high-quality treatment plan.
The new production line is expected to be put into use at the end of 2022. After the completion of the project, the annual production capacity of the Beijing plant is expected to increase by about 40%, once again strengthening its important position as one of the world's most advanced production bases for Bayer prescription drugs.
In 1995, Bayer Prescription Drugs built its first pharmaceutical production and packaging plant in the Beijing Economic and Technological Development Zone. In 2016, the comprehensive expansion project of Bayer's prescription drugs Beijing factory with an investment of about 100 million euros was officially launched, making it the world's largest pharmaceutical packaging base for Bayer prescription drugs.
The production capacity improvement project includes a production area and a supporting technology area. It will be equipped with a new fully automated high-speed production line and a supporting fully automated logistics system, aiming to build a world-class manufacturing plant.
